On May 15. 2023 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases – including COVID-19, the disease caused by the SARS-CoV-2 virus – reported its financial results for the first quarter 2023 and provided a business update (Press release, AIM ImmunoTech, 15 15, 2023, View Source [SID1234631698]). As previously announced, the Company will host a conference call and audio webcast on Tuesday, May 16, 2023, at 8:30 AM ET (details below).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The significant progress we have made advancing Ampligen through numerous human clinical studies in multiple indications has provided us with a growing body of positive data. These data have supported and guided the prioritization of our oncology pipeline, with pancreatic cancer as our lead development program," commented Thomas K. Equels, Chief Executive Officer of AIM. "With a strong cash position and a fundamental plan to execute across our pipeline, we are positioning the Company to achieve a number of value-driving milestones in the near term."
Recent Highlights
Appointed preeminent biotechnology pioneer W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)
Nancy K. Bryan, pharmaceutical industry veteran, appointed to Board of Directors
Received central Institutional Review Board ("IRB") approval for the protocol of Phase 2 study evaluating Ampligen as a therapeutic for patients with post-COVID conditions ("AMP-518")
Expected Upcoming Pipeline Milestones
Q2 2023
Locally Advanced Pancreatic Cancer: Enroll first patient in Phase 2 study
Post-COVID Conditions: Enroll and dose first patient in Phase 2 study
Q3 2023
Advanced Recurrent Ovarian Cancer: Announce protocol-planned interim results
Q4 2023
Metastatic Pancreatic Cancer: Begin clinical trial
Post-COVID Conditions: Enroll last patient in Phase 2 study
Summary of Financial Highlights for First Quarter 2023
As of March 31, 2023, AIM reported cash, cash equivalents and marketable securities of $30.8 million. Based on management’s current expectation, the Company’s cash runway is expected to fund operations through multiple key milestones through the end of 2024.
Research and development expenses for the three months ended March 31, 2023 were $2.1 million, compared to $1.0 million for the same period in 2022.
General and administrative expenses were $2.3 million for the three months ended March 31, 2023, compared to the $2.1 million for the same period 2022.
The net loss from operations for the three months March 31, 2023 was $3.7 million, or $0.08 per share, compared to $3.8 million, or $0.08 per share, for the three months ended March 31, 2022.
Please refer to the full 10-Q for complete details.
Conference Call and Webcast Details
As previously announced, the Company will host a quarterly conference call and live audio webcast to discuss the operational and financial results on May 16, 2023, at 8:30 AM ET.
The call will be hosted by members of AIM, CEO Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The live webcast will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com, and will be archived for 90 days following the live event.